The present study compared the T-cell progenitor content of CD34+ lineage (Lin)-cells isolated from normal adult bone marrow (ABM) and mobilized peripheral blood (MPB). Both cell populations were found to differentiate into T cells when injected into human fetal thymi implanted into severe combined immunodeficient mice. Cytokine-MPB cells were less efficient than ABM cells in engrafting in the fetal human thymus, although both gave rise to thymocytes with identical phenotypes based on the analysis of CDla, CD3, CD4, and CD8 expression. Thymocytes derived from adult CD34' UTOLOGOUS mobilized peripheral blood (MPB) progenitor cells provide hematologic rescue after highdose chemoradi~therapy.'-~ MPB cells are collected by apheresis after rebound from myelosuppressive chemotherapy andlor cytokine administration such as granulocyte colonystimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF).'0"3 MPB contains CD34' cells as well as myeloid progenitors such as colony-forming unit-GM (CFU-GM), CFU-mixed (CFU-mix), and burst-forming unit-erythroid (BFU-E)."." When associated with cytoreductive therapies, cytokine administration augments the MPB CD34+ cell content and the myeloid progenitor cell pool, as evidenced by increased numbers of assayable CFU-GM, BFU-E, and CFU-mix."^" Transplantation of MPB cells reduces the duration of neutropenia and thrombocytopenia to a greater extent than the reinfusion of bone marrow (BM).'4 However, because of its large progenitor content and because of the accelerated recovery that occurs after its infusion compared with that of BM, it remains unanswered whether human MPB contains hematopoietic stem cells. Hematopoietic stem cells can be defined by their capacity to provide longterm repopulation of multiple blood cell lineages including myeloid and lymphoid cells. In mice, the presence of circulating long-term repopulating multipotent stem cells has been clearly do~umented.'~"~ In humans, indirect evidence for the presence of such cells is gathered from several observations. MPB contains long-term culture initiating cells (LTCIC),I3 thought to be the best qualitative estimate of human hematopoietic stem cells.'' Successful hematologic reconstitution is achieved when MPB cells are used as the sole hematologic support after high-dose chemotherapy,"' particularly follow- 
UTOLOGOUS mobilized peripheral blood (MPB) progenitor cells provide hematologic rescue after highdose chemoradi~therapy.'-~ MPB cells are collected by apheresis after rebound from myelosuppressive chemotherapy andlor cytokine administration such as granulocyte colonystimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF).'0"3 MPB contains CD34' cells as well as myeloid progenitors such as colony-forming unit-GM (CFU-GM), CFU-mixed (CFU-mix), and burst-forming unit-erythroid (BFU-E)."." When associated with cytoreductive therapies, cytokine administration augments the MPB CD34+ cell content and the myeloid progenitor cell pool, as evidenced by increased numbers of assayable CFU-GM, BFU-E, and CFU-mix."^" Transplantation of MPB cells reduces the duration of neutropenia and thrombocytopenia to a greater extent than the reinfusion of bone marrow (BM). '4 However, because of its large progenitor content and because of the accelerated recovery that occurs after its infusion compared with that of BM, it remains unanswered whether human MPB contains hematopoietic stem cells. Hematopoietic stem cells can be defined by their capacity to provide longterm repopulation of multiple blood cell lineages including myeloid and lymphoid cells. In mice, the presence of circulating long-term repopulating multipotent stem cells has been clearly do~umented.'~"~ In humans, indirect evidence for the presence of such cells is gathered from several observations. MPB contains long-term culture initiating cells (LTCIC),I3 thought to be the best qualitative estimate of human hematopoietic stem cells.'' Successful hematologic reconstitution is achieved when MPB cells are used as the sole hematologic support after high-dose chemotherapy,"' particularly follow-ing presumed myeloablative regimens including total body irradiation.' More recently, it has been shown that transplantation of CD34+ MPB cells can restore and sustain hematopoiesis after myeloablative chemotherapy," thus confirming that as in BM, the hematopoietic progenitor cells are contained in a minor fraction of the tissue. Despite this evidence, direct proof of the existence of a cell with true long-term marrow repopulating ability in human MPB is lacking. In particular, the contribution of MPB progenitor cells to multilineage engraftment has not been fully evaluated in humans. It is clear that MPB possesses a large number of myeloid (granulocytic, monocytic, erythroid, and megakaryocytic) progenitor cells, but information on the lymphoid and, more specifically, on the T-cell progenitor content is lacking. There is a markedly accelerated recovery of lymphocyte counts and CD3' T cells after autologous MPB cell transplantation as opposed to allogeneic BM transplantation'"; however, true T-cell differentiation from a progenitor cell cannot be assessed because of the large proportion of T cells already present in MPB grafts. Although the stages and sites for T-cell commitment during hematopoietic stem cell differentiation remain unclear, it is commonly accepted that mature T cells are primarily generated after thymic processing where they differentiate from an intrathymic CD34+ progenitor ce112'~22 and acquire a number of cellsurface molecules including CDla, CD4, CD8, and of CD3 associated to the T-cell receptor (TCR) aP or y6 complexes."~2' Human T-cell differentiation can be experimentally reproduced. Fetal liver or fetal BM CD34' cells differentiate into T cells when injected into an allogeneic thymus where T-cell development can be supported either in vitro for short periods of time" or in vivo into a surrogate severe combined immunodeficient (SCID) mouse, for a more extended period of time.24 Thus far, no equivalent study has explored the potential of adult cells to differentiate into T cells via an intrathymic stage. This prompted us to examine the T-cell progenitor activity in adult CD34+ MPB cells and compare it with that of CD34' cells isolated from ABM. (Table l) , and consisted of a 10-mL sample containing approximately 2 to 13 X 10' mononuclear cells. Peripheral blood from these patients was mobilized with either recombinant human G-CSF (Filgrastim; Amgen, Thousand Oaks, CA) alone or a combination of etoposide and G-CSF. G-CSF was administered by daily subcutaneous injections at 10 pgkgld. Leukapheresis was begun 4 days later. For chemotherapy plus growth factor mobilization, patients were treated with etoposide (2 g/m2) administered as a single intravenous (IV) infusion over 4 hours. The next day, G-CSF was administered as described above. Leukapheresis was initiated when the white blood cell (WBC) count was greater than 1,000 cells/pL. Leukapheresis was performed using a Cobe Spectra 2991 system (Cobe Laboratories, Inc, Lakewood, CO). Human fetal liver (FL) was obtained with informed consent from Advanced Bioscience Resources Inc (Alameda, CA). Sample processing and staining for $ow cytometry sorting. ABM low-density (< 1.077 g/mL) mononuclear cells (Lymphoprep; Nycomed Pharma, Oslo, Norway) were washed twice in staining buffer (SB) consisting of phosphate-buffered saline (PBS) and 0.2% bovine serum albumin (BSA). The sample was then incubated for 10 minutes with 1 mdmL heat-inactivated human gammaglobulin (Gamimune; Miles Inc, Elkhart, IN) to block Fc receptor binding of mouse antibodies. The cells were depleted of granulocytes by incubation with CD15 monoclonal antibodies (MoAbs) (Medarex, West Lebanon, NH) immobilized on magnetic beads (Dynal M450; Dynal, Oslo, Norway). Some samples were further depleted of T cells with anti-CD2-coated magnetic beads (Dynal). For immunostaining, anti-CD34 MoAbs (Tiik-3) obtained from A. Ziegler (University of Berlin, Berlin, Germany) or IgG3 isotype control MoAbs were added at 0.3 pg per IO6 cells in a total volume of 0.5 mL SB for 20 minutes on ice. Cells were washed twice in SB, then incubated with Texas Red-conjugated goat antimouse IgG3 antibodies (Southem Biotechnologies Associates, Birmingham, AL) and fluorescein isothiocyanate (FITC)-labeled antiglycophorin A (Amac, Westbrook, ME), CD2, CD14, CD15, CD16, and CD19 or CD20 (Becton Dickinson, San Jose, CA) MoAbs for 20 minutes on ice followed by three washes in SB. Cells were sorted using the FACStar Plus cell sorter (Becton Dickinson) equipped with dual argon ion lasers, the primary emitting at 488 nm and a dye laser (Rhodamine 6G) emitting at 600 nm (Coherent Innova 90, Santa Clara, CA). MPB samples generally contained relatively few red blood cells, but had large numbers of granulocytes that were removed either by counterflow centrifugal elutriation followed by CD15 magnetic bead depletion or by freezing and thawing. Fresh MPB samples were elutriated with a JE5.0 Beckman counterflow elutriator equipped with a Sanderson chamber (Beckman, Palo Alto, CA). Cells were resuspended in elutriation medium (Biowhittaker, Walkersville, MD) at pH 7.2, supplemented with 0.5% human serum albumin (HSA) (Gemini, Calabasas, CA). The rotor speed was set at 2,000 rpm, the cells were introduced, and the first fraction collected at a flow rate of 9.6 mL/min. Fractions 2 and 3 were collected at the respective flow rates of 14 and 16 mL/min. The rotor was then stopped and a rotoroff fraction collected. Cells were resuspended in RPMI (JRH Biosciences, Lenexa, KS) containing 5% HSA, 10 pg/rnL DNAse I (Boehringer Mannheim, Indianapolis, IN), and penicillidstreptomycin (P/ S ) (50 U/mL and 50 pg/mL, respectively). Fractions 2 and 3 were pooled and after a blocking step to avoid nonspecific Fc binding, depleted of remaining granulocytes with anti-CD15-coated magnetic beads as described above. Frozen MPB samples were cryopreserved at -80°C in 10% dimethyl sulfoxide (DMSO; Sigma, St Louis, MO) before processing. After being thawed rapidly at 37°C and centrifuged over a Ficoll gradient (Ficoll Paque; Pharmacia, Piscataway, NJ), the cells between density 1.040 and 1.068 g/mL were collected; washed in RPMI, HSA, and DNAse, and did not need further depletion of granulocytes. To enrich for CD34+ MPB cells before flow cytometty sorting, we depleted Lin' cells, particularly CD2' cells. MPB cell samples were T-cell depleted by treatment with anti-CD2-coated magnetic beads (Dynal). In some cases, a more thorough depletion of the Lin+ population before sorting was achieved by incubating the cells with FITC anti-CD2, -CD14, -CD15, -CD16, -CD19, and -glycophorin A MoAbs as described above, followed by two washes in SB, and incubation with sheep antimouse Ig beads (Dynal). Bound cells were discarded. For sorting, cells were stained with anti-CD34 antibodies (Tiik-3) recognized with a goat antimouse IgG3-Texas Red conjugate, and FITC-Lin MoAbs consisting of anti-CD2, -CD14, -CD15, -CD16, -CD19, and -glycophorin A MoAbs. FL was ficolled, Lin-depleted, and stained for CD34.
SCID-hu thymus assay. As reported previously,z' 18-to 24-week-old fetal thymi were dissected and fragments containing two to four intact lobules were placed on nitrocellulose filters (0.8 pm; Costar Corp, Cambridge, MA) on top of gelatin rafts (Gelfoam; Upjohn, Kalamazoo, MI) in RPMI medium containing 10% fetal calf serum (FCS) and P/S. A sample of thymocytes was taken for HLA immunophenotyping of the recipient thymus with FITC-conjugated MoAbs to HLA molecules MA2.1, BB7.2, GAP-A3, and W6/ 32 derived from hybridomas obtained from American Type Culture Collection (ATCC) (Rockville, MD). After 7 days of incubation at 25°C and 5% COz, thymus fragments were irradiated with 250 rads from a '"CS source (JL Shepherd and Associates, San Fernando, CA), washed, and immediately micro-injected with the HLA-mismatched sorted candidate pre-T cell populations in a 1 +L v01 using an oil-filled micro-injector (Narishige, Tokyo, Japan) and l-mm diameter glass micropipets (World Precision Instruments, Sarasota, FL). Fragments were placed back on the filters and incubated at 37°C. 5% CO2 overnight and then inserted under the kidney capsule of anesthetized 6-to 8-week-old C.B-17 scidscid (SCID) mice bred in our facilities. Mice were killed 6 to 8 weeks after transplantation and the thymus grafts were recovered, reduced to a single cell suspension, and subjected to three-color immunofluorescence analysis on the FACScan (Becton Dickinson). The following MoAbs were used: FITC-conjugated anti-HLA antibodies, -CD2, or FITC mouse IgGl irrelevant control (Becton Dickinson); phycoerythrin (PE)-conjugated anti-CDla (RT6) (Coulter, Hialeah, FL); PE anti-W6/32 and PE anti-CD4 or PE antimouse IgGl control (Becton Dickinson); and Tricolor (TC)-conjugated anti-CD45, -CD& -CD3, or mouse IgGl irrelevant control from Caltag (South San Francisco, CA).
T-cell cultures from SCID-hu thymus grafts. To expand mature T cells from SCID-hu thymus grafts, approximately 1 X lo5 thymocytes were cultured in RPMI with 10% FCS, 2 mmol/L L-glutamine, and PIS in the presence of an equal volume of a feeder cell mixture composed of irradiated (3,500 rads) peripheral blood leukocytes (2 X 106/mL) that expressed none of the antigens recognized by our panel of anti-HLA MoAbs, irradiated (5,500 rads) JY cells (2 X 105/mL), and phytohemagglutinin (PHA) (GIBCO, Grand Island, NY) as de~cribed.~' Cultures were subsequently maintained with 50 ng/mL human recombinant interleukin-2 (L-2; Sandoz Pharma, Basel, Switzerland) twice a week. Cultured T-cell blasts were stained FACstar Plus with dual laser as described above.
RESULTS
We studied the T-cell progenitor content of G-CSF-MPB obtained from eight patients, 5 of whom were diagnosed with non-Hodgkin's lymphoma (NHL) and 3 with breast carcinoma (BC) ( Table l) . The NHL patients were mobilized with G-CSF alone (10 pglkgld for 4 days) and leukapheresis was begun 4 days after administration of the cytokine. Most BC patients were mobilized with etoposide ( 2 g/m2) and G-CSF (10 pg/kg/d), and apheresis was initiated after recovery of WBC counts to 1,000 cells/pL. Samples were collected on successive days after the start of leukapheresis (Table  1) . For comparison, we also examined the T-cell progenitor content of ABM obtained from normal volunteers.
The immunophenotype of MPB was notably different from that of ABM. Low-density ABM cells depleted of CD15' granulocytes had 4% to 8% CD34' cells, whereas the MPB samples contained from 0.3% to 1.5% CD34' cells within the erythrocyte and granulocyte-depleted PB fractions in the lymphoblastoid region. The percentage of CD34' cells was notably enriched following Lin' cell depletion before sorting. Unlike ABM, MPB had few CD19' or CD20' B cells," but contained large proportions of CD2' T cells and CD14' monocytes.
Throughout our study, we used an extended combination of Lin-MoAbs covering all mature lineages including those present at low to undetectable numbers (CD19' B cells and glycophorin A' erythroblasts) for reasons of uniformity with our BM study and to eliminate potential malignant cells, particularly in the case of B-cell lymphomas. The sorted cell purity was usually greater than 95%. Also, MPB CD34+ Lin-cells (Lin always includes CD2) were virtually devoid of cells bearing other T-cell markers such as CD7 or CD1 (data not shown), thus confirming the purity of the sorted population and the absence of cells obviously committed to the T-cell lineage.
The ability of sorted cell populations to generate T cells was tested in the SCID-hu thymus assay. Allogeneic (MHC mismatched) CD34+ Lin-cells (donor cells) were microinjected into a host T-cell-depleted thymus subsequently implanted into SCID mice. Each thymus graft received 1 X lo4 CD34+ Lin-MPB or ABM cells, a number previously determined to be optimal for reconstitution with fetal CD34' cells, and the phenotype of cells present in the graft was examined 6 to 8 weeks after injection. Donor-derived T cells were generated from both ABM and MPB CD34' Lin-populations (Fig 1A) . ABM and MPB CD34' Lin-. populations differed in their capacity to reconstitute in the SCID-hu thymus assay in that 100% of donors of ABM samples (n = 6) produced at least one thymus graft containing more than I % donor-derived T cells, compared with 82% of donors (n = 8) of CD34' MPB cells. Also, injection of 1 X lo4 ABM CD34' Lin-cells resulted in a 73% graft success rate (calculated as the percentage of grafts containing more than 1% donor-derived T cells among the grafts analyzed) whereas injection of 1 X lo4 CD34' Lin-MPB cells had only a 5 1 % graft success rate. Identical numbers of fetal BM or FL CD34' cells taken as positive controls always engrafted (data not shown). We confirmed that CD34-cells isolated from either MPB or ABM did not engraft in our assay (data not shown). The level of thymic reconstitution from adult CD34' cells as assessed by the percentage of donor-T cells in the positively reconstituted grafts was high (75% i-33%), and these values were remarkably identical between ABM and MPB cells. Taken together, these data indicate that ABM and MPB cells have a similar ability to produce T cells, but at equal cell numbers MPB CD34' cells do not engraft as frequently as ABM CD34' cells. One possible explanation is that MPB contains a lower number of T-cell progenitors than ABM within the CD34' Lin-population. Alternately, MPB cells were obtained from diseased patients who have received cytotoxic or chemotherapeutic agents that may be potentially detrimental to T-cell development.
We determined if the underlying disease of the patients from whom the MPB grafts were obtained could affect the T-cell reconstitution potential and therefore account for the discrepancy between the success rates of MPB and ABM. Figure 1B compares the NHL and BC patient groups for the percentage of donor-derived T cells in each SCID-hu thymus graft injected with lo4 CD34' Lin-MPB cells. The graft success in the three BC patients studied (40%) was lower than with NHL patients (64%), but we observed a higher, although not significantly different, average percentage of donor T cells in the positive grafts from BC patients (92% 2 6%) than from NHL patients (79% -+ 28%). In conclusion, there does not seem to be a large difference between the Tcell reconstitution potential of T-cell progenitors isolated from the blood of BC versus NHL patients. Furthermore, T cells can be generated from CD34' Lin-MPB cells of patients with various neoplasias.
The quality of donor-derived thymopoiesis was analyzed by expression of known thymocyte antigens on donor-derived cells generated in the SCID-hu grafts. In Fig 2, representative grafts reconstituted with CD34' Lin-cells from MPB, ABM, or FL showed high percentages of donor-derived thymocytes, and also contained HLA class I bright terminally differentiated host thymocytes. T cells generated from either MPB or ABM were all positive for CD2 (not shown) and expressed high levels of CDla, with graded levels of CD3, and most cells coexpressed the CD4 and CD8 molecules (Fig 2) , thus having the classical phenotype of cortical thymocytes.** Based on these parameters, the composition of thymi reconstituted with adult tissues was very similar to that of fresh fetal or pediatric thymi" (and our own unpublished observations, September 1992). Also, both A PB ABM and MPB cells generated mature thymocytes displaying high CD3 and HLA class I expression, and with CD4 or CD8. However, a much lower percentage, but not complete absence, of CD8 single-positive (CD8+ CD4-) thymocytes was observed in thymus grafts reconstituted with either ABM or MPB cells as opposed to fetal liver (Fig 2) . This was not because of the analysis of lower numbers of cells. The experiments using fetal liver CD34+ cells indicate that the recipient thymus is not the cause for lack of CD8+ CD4-thymocyte production, but rather suggest that the defect may occur at the level of the adult T-cell progenitor population itself. To confirm that adult tissues could indeed produce the whole spectrum of mature T cells, including mature CD3+ and TCR+ cells expressing either the y6 or (YO receptors with the associated molecules CD4 and CD8, we cultured thymocytes in the presence of a feeder cell mixture with PHA and IL-ZL2' In all cases (a total of seven experiments) donor-derived thymocytes grew vigorously in response to the stimuli, demonstrating a functional response. Samples were analyzed by four-color immunofluorescence for expression of TCR cup and TCR y6, CD4, and CD8 in the donor population (Fig 3) . Both ABM and MPB-reconstituted thymus grafts could generate donor-derived mature T cells expressing either the (YO TCR or the y6 TCR in association with CD3 (as shown in Fig 3, C and D , with a representative thymus graft reconstituted with MPB CD34+ Lin-cells).
Donor-derived CD3+, TCR (YO+ T cells expressed CD4 or CD8 (Fig 3E) , the phenotype of mature T cells, whereas most of the CD3+, TCR yS+ cells were negative for CD4 and CD8 (Fig 3F) , similar to what has previously been reported in the literature for most yS T cells.23 Identical findings were observed with cultured SCID-hu thymic grafts reconstituted with ABM cells (not shown). These data show that adult CD34+ cells obtained from ABM or MPB can generate polyclonal T cells that are functional in the context of a strong proliferative response to alloantigens, mitogens, and IL-2.
DISCUSSION
The data presented here show that adult CD34+ Lin-cells, isolated from both ABM and MPB, have the capacity to (and our own unpublished observations, September 1992). Based on these parameters, early adult and fetal thymopoiesis seem identical. However, we observed a reduction in the ability of adult CD34+ cells, as opposed to fetal CD34' cells, to generate the more mature CD8 single-positive (CD8+ CD4-) thymocyte subset. Fetal liver CD34+ cells used in the same experiments show that the recipient thymus is not responsible for the lack of CD8+ CD4-thymocyte production, but rather that the defect may be occurring at the level of the adult T-cell progenitor population itself. It is possible that fetal cells are more able to produce factors implicated in the maturation of CD8 cells, or that inversely some adult cells have an inhibitory effect. It has been shown using allogeneic SCIDhu thymusdiver constructs, that fetal cells can be positively selected by the host epithelium and negatively selected by the donor-derived accessory cells.25 Because adult cells may have a restricted ability to generate both T cells and accessory thymic cells, it is possible that aberrant positive or negative selection occurs. We are currently investigating these possibilities.
As shown with SCID mice constructed with fetal thymus and fetal liver, it is possible to expand in vitro mature and functional human T cells that were generated in a xenogeneic system. 26 In the present study, we characterized in vitro, adult donor-derived mature CD3' T cells expressing the TCR yS or the TCR (YO with either CD4 or CD8. This confirmed that T-cell maturation from adult CD34' cells could be completed to the final stages of thymic differentiation, and that the progeny of adult CD34+ cells was polyclonal and functional. We have observed true T-cell differentiation and not expansion because CD34+ Lin-MPB cells were not clonogenic in vitro using our T-cell expansion conditions (A.H.M.G., unpublished observations, April 1993), but upon intrathymic transfer, acquired specific T-cell mark- manS.12.13.15.1h G-CSF-MPB CD34' cells have been reported to contain committed myeloid precursors giving rise to all myeloid lineages (granulocytes, monocytes, erythroid cells, and megakaryocytes), as well as the more primitive myeloid progenitors CFU-mix and LTCIC." Our data correlate with studies in mice where G-CSF-MPB cells have long-term reconstituting ability in hematopoietic organs, including the thymus.'' The T-cell progenitor potential of normal ABM and G-CSF-MPB cells was found to be qualitatively very similar, suggesting that G-CSF as a mobilization agent does not impair stem cell differentiation along the lymphoid pathway by inducing an irreversible commitment to the myeloid lineages. The present study reinforces earlier reports showing that MPB and ABM contain qualitatively equivalent in vitro primitive hematopoietic activity" and can both provide long-term hematopoietic reconstitution after severe myeloFor personal use only. on November 11, 2017 . by guest www.bloodjournal.org From For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From
